AI-generated summary
The authors compared 308-nm monochromatic excimer light with localized 311-nm narrow-band UVB for vitiligo in a randomized, intrapatient trial with 11 patients. They report that 20 percent of NB-UVB-treated lesions reached over 50 percent repigmentation, while none of the MEL-treated lesions did after 24 sessions. The study was small, so these findings should be interpreted with caution.
- Participants
- 11
- Who or what was studied
- Patients with vitiligo (11 patients, 3 lesions each)
- Wavelengths
- 308, 311 nm
- Limits stated in the abstract
- The abstract describes a small sample of 11 patients and does not report statistical comparisons or confidence intervals.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on karger.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Randomized controlled trial, Phototherapy, Placebo-controlled, Ultraviolet. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.